Luisa Bopp

Dr. Luisa Bopp

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Science Advances
Verified
Journal Article
Open access
MAManuel Huerta Arana
Manuel Huerta Arana
HKHenning Klapproth
Henning Klapproth
MSMichal A. Stanczak
Michal A. Stanczak
LBLuisa Bopp
Luisa Bopp
KWKarla Witschurke
Karla Witschurke
MFMario Fabri
Mario Fabri
Granuloma annulare (GA) and cutaneous sarcoidosis (cSAR) have an overlapping immunopathology, in which the aberrant activation of macrophages by IFN-γ constitutes a central driver. Nevertheless, the molecular understanding in GA and cSAR macrophages remains limited. We reanalyzed single-cell RNA sequencing data of GA and cSAR and performed in vitro experiments with primary human cells showing that oxidative phosphorylation (OXPHOS) is a dominant metabolic pathway in IFN-γ–activated macrophages. Furthermore, we identify an IFN-γ–induced response network in GA and cSAR macrophages, sensitive to electron transport chain (ETC) inhibitors. Guanylate-binding protein 1 (GBP1) was central in controlling IFN-γ–mediated macrophage activation. Meanwhile, inhibition of IFN-γ signaling, ETC complexes, and GBP1 reduced granuloma formation in a human in vitro model. Metformin, a clinically used ETC complex I inhibitor, suppressed IFN-γ activation of macrophages and in vitro granulomas. Together, we suggest that OXPHOS and GBP1 represent druggable targets in granulomatous diseases and that drug repurposing of metformin is a possible strategy.

8 December 2023 in Die Dermatologie
Verified
Journal Article
Closed access
PDF file
SMSebastian Mrosik
Sebastian Mrosik
HRHeinrich Rasokat
Heinrich Rasokat
MFMario Fabri
Mario Fabri
LBLuisa Bopp
Luisa Bopp

6 January 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
PDF file
LBLuisa Bopp
Luisa Bopp
NDNicolai Deresz
Nicolai Deresz
MFMario Fabri
Mario Fabri
ESEsther von Stebut
Esther von Stebut
Click on the article title to read more.

13 February 2026 in Die Dermatologie
Verified
Journal Article
Closed access
PDF file
CDCarla Dewald
Carla Dewald
RFRobin Fischer
Robin Fischer
DSDaniel Smarsly
Daniel Smarsly
LBLuisa Bopp
Luisa Bopp

12 September 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
HKHenning Klapproth
Henning Klapproth
MAManuel Huerta Arana
Manuel Huerta Arana
JLJan-Wilm Lackmann
Jan-Wilm Lackmann
LBLuisa Bopp
Luisa Bopp
Muhammad Sajid HussainMuhammad Sajid Hussain
Muhammad Sajid Hussain
MFMario Fabri
Mario Fabri
Necrobiotic xanthogranuloma (NXG) represents a rare granulomatous skin disease characterized by IFN-γ-activated macrophages with limited treatment options. This study shows that metformin not only suppresses IFN-γ-induced macrophage activation, but also induced clinical remission in a patient with NXG. These findings highlight metformin as a promising candidate for therapeutic repurposing in NXG.

13 May 2022 in Die Dermatologie
Verified
Journal Article
Open access
PDF file
LBLuisa Bopp
Luisa Bopp
AKAlexander Kreuter
Alexander Kreuter
ESEsther von Stebut
Esther von Stebut
MFMario Fabri
Mario Fabri
Zusammenfassung Dermatologische Erkrankungen gehören zu den häufigsten reiseassoziierten Erkrankungen. Einen großen Stellenwert haben insbesondere virale Infektionen mit tropischen und subtropischen, aber auch hierzulande vorkommenden Erregern, die häufig mit Exanthemen und Allgemeinsymptomen einhergehen. Neben genauen anamnestischen Angaben über den Reiseverlauf und mögliche Risikoexpositionen sowie einer gründlichen klinischen Untersuchung ist insbesondere die Kenntnis über länderspezifische Risiken wichtig, um in Kombination mit molekularbiologischen und serologischen Untersuchungen die korrekte Diagnose zu stellen. Anhand eines Fallbeispiels gibt dieser Beitrag eine Übersicht über wichtige virusbedingte Exantheme, die insbesondere bei Reiserückkehrern auftreten können.